GlassScriptPhysician profile
Robert F Morrison
NPI 1235111857
$2,526.61
in general payments reported to CMS, 2019-2025
15 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $309 · 2021: $140 · 2022: $23.62 · 2023: $284 · 2024: $236 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $821.28 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $386.03 | 2019-2021 | |
| Amgen INC. | $302.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $230.26 | 2019-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $228.16 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $136.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.74 | 2025 | |
| Amarin Pharma, INC. | $79.01 | 2019-2021 | |
| Pfizer INC. | $72.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $55.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.80 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $30.00 | 2019 | |
| Impulse Dynamics (USA) INC. | $23.62 | 2022 | |
| Novo Nordisk INC | $23.27 | 2023 | Ozempic, Rybelsus |
| Preventice Services, LLC | $22.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.